First FDA-approved 3-D manufactured drug hits the market

The first FDA-approved drug produced using 3-D printing is now on the market. Aprecia Pharmaceuticals said this week that it has launched its epilepsy drug, Spritam, that is manufactured through three-dimensional printing technology. Spritam is a formulation of levetiracetam that uses the process so the pills rapidly disintegrate with a sip of liquid, making them easier to swallow. Aprecia has two facilities for manufacturing, one in Blue Ash, OH, where the company is headquartered, and one in East Windsor, NJ. A spokesperson said the company is currently investing $25 million in its 190,000-square-foot Blue Ash manufacturing facility. Release

Suggested Articles

Drugmakers have voluntarily recalled their generic Zantac from the U.S. market after the FDA raised concerns, but it has not been without a cost.

Just weeks after selling the sterile manufacturing assets of its Kyowa operation in Japan, it has unloaded the rest of its Kyowa drugmaking operation.

India’s Aurobindo, which has yet to close its $1 billion deal to buy 300 Sandoz products in the U.S., continues to rack up FDA issues.